Safety and Efficacy of Low-dose Terlipressin Delivered by Continuous Intravenous Infusion in Patients With Cirrhosis and Ascites Refractory to, or Intolerant of, Diuretic Therapy, Requiring Large Volume Paracentesis

Trial Profile

Safety and Efficacy of Low-dose Terlipressin Delivered by Continuous Intravenous Infusion in Patients With Cirrhosis and Ascites Refractory to, or Intolerant of, Diuretic Therapy, Requiring Large Volume Paracentesis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Terlipressin (Primary)
  • Indications Ascites; Liver cirrhosis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors BioVie
  • Most Recent Events

    • 11 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 25 Apr 2017 According to a BioVie media release, Jasmohan Bajaj is the principal investigator of this trial.
    • 11 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top